| Literature DB >> 26409275 |
Angela M Starks1, Enrique Avilés2, Daniela M Cirillo3, Claudia M Denkinger4, David L Dolinger4, Claudia Emerson5, Jim Gallarda6, Debra Hanna2, Peter S Kim7, Richard Liwski2, Paolo Miotto3, Marco Schito2, Matteo Zignol8.
Abstract
Continued progress in addressing challenges associated with detection and management of tuberculosis requires new diagnostic tools. These tools must be able to provide rapid and accurate information for detecting resistance to guide selection of the treatment regimen for each patient. To achieve this goal, globally representative genotypic, phenotypic, and clinical data are needed in a standardized and curated data platform. A global partnership of academic institutions, public health agencies, and nongovernmental organizations has been established to develop a tuberculosis relational sequencing data platform (ReSeqTB) that seeks to increase understanding of the genetic basis of resistance by correlating molecular data with results from drug susceptibility testing and, optimally, associated patient outcomes. These data will inform development of new diagnostics, facilitate clinical decision making, and improve surveillance for drug resistance. ReSeqTB offers an opportunity for collaboration to achieve improved patient outcomes and to advance efforts to prevent and control this devastating disease. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.Entities:
Keywords: Mycobacterium tuberculosis; database; drug resistance
Mesh:
Substances:
Year: 2015 PMID: 26409275 PMCID: PMC4583571 DOI: 10.1093/cid/civ610
Source DB: PubMed Journal: Clin Infect Dis ISSN: 1058-4838 Impact factor: 9.079